



**FACTSHEET**

**MAXA 2010  
Growth Award**

<b>Company</b>	Biosensors Interventional Technologies Pte Ltd
<b>Boiler-Plate</b>	<p>Biosensors Interventional Technologies Private Limited (“BIT”) is a fully-owned subsidiary and operational hub of SGX-listed Biosensors International Group, Ltd (“Biosensors” or “Group”). BIT produces the Group’s interventional cardiology products, including the flagship BioMatrix™ and BioMatrix Flex™ drug-eluting stents (“DES”), which are used to treat patients suffering from coronary artery disease, a serious and potentially fatal condition that affects hundreds of millions people worldwide.</p> <p>Biosensors’ commitment to manufacturing excellence is at the heart of its clinical and commercial success. BIT, the group’s manufacturing center for interventional cardiology products, is a key part of this commitment, consistently delivering high quality products and exceeding customer expectations while at the same time reducing costs.</p>
<b>Recent Announcements</b>	<ul style="list-style-type: none"> <li>• August - Biosensors received approval for sale of BioMatrix drug eluting stent system in Taiwan</li> <li>• June - Acquisition of certain assets of CardioMind providing access to a stent system and technology with the potential for use in small vessels throughout the body, including coronary, peripheral and neurological applications</li> <li>• May - BioMatrix Flex™ drug eluting stent system launched across major European markets and selected regions in the Middle East, Africa and Asia</li> </ul>

Award Partners: Singapore Economic Development Board . McKinsey & Company . Singapore Manufacturing Federation . Singapore-MIT Alliance

250 North Bridge Road, #28-00 Raffles City Tower, Singapore 179101  
Tel: 65 6832 6832 | Fax: 65 6832 6565 | email: [maxa@edb.gov.sg](mailto:maxa@edb.gov.sg) | Website: [www.maxa.sg](http://www.maxa.sg)

<p><b>Leadership Position (Global/Asia)</b></p>	<ul style="list-style-type: none"> <li>• Industry First: First to launch a biodegradable polymer DES incorporating internally developed anti-restenotic drug, Biolimus A9™</li> <li>• 2009 Deloitte &amp; Touche: Top 500 Fastest Growing Technology Companies in Asia Pacific</li> <li>• 2006 Medical Device and Diagnostic Industry Magazine: One of “50 Companies to Watch”</li> <li>• Landmark real-world LEADERS trial demonstrated equivalent safety and efficacy of the BioMatrix Flex stent as compared to the leading stent at the time of the study, Johnson &amp; Johnson’s Cypher® Select™ DES.</li> </ul>
<p><b>Efforts to Achieve Manufacturing Excellence</b></p>	<p>Biosensors’ focus on innovation has led to many improved manufacturing processes and systems, including its proprietary automated micro-pipette coating process (“AMPC”). This high-precision, abluminal stent coating method - developed in-house - has enabled consistent drug coating onto the stent surface and has significantly increased productivity. The company also uses continuous improvement and lean-manufacturing programs to improve productivity and reduce cycle times.</p>